Smith Ian F

Smith Ian F is listed in filings as Interim CEO at Stoke Therapeutics, Inc.. This profile follows SEC Form 4 activity through Feb 19, 2026, including 7 public disclosures. Recent filings connect the profile to Stoke Therapeutics, Inc. (STOK) and Foghorn Therapeutics Inc. (FHTX). The current snapshot covers public activity from Jun 28, 2024 to Feb 19, 2026. Reported amounts are shown as $2.0M to $6.0M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.